Oleoylethanolamide (OEA) for extemporaneous compounding only
- Australia-first supply of Trpti OEA™, a next-generation oleoylethanolamide (OEA)
- OEA is an endogenous fatty acid amide, synthesised in the small intestine, and classified as a bioactive mono-unsaturated lipid mediator within the acylglycerol and N-acylethanolamine families
- LipiSperse® delivery technology to address the bioavailability limitations of standard OEA
- Trpti OEA™ research reference dose: 125 mg twice daily (250 mg per day)
- Vegan Friendly
Health Focus: Endocrine/Metabolism, Foundational Health, GI-Map Test, Immune Support, Women’s Health
Free From: No Added Dairy, No Added Gluten, No added Soy, Sulphite free, Vegan Friendly, Vegetarian Friendly
